QPPV Interview Questions

QPPV interviews frequently focus on oversight, governance, compliance, inspections and practical leadership experience.

Common QPPV Interview Questions

• What are the responsibilities of a QPPV?
• How do you maintain oversight of a global PV system?
• How do you monitor compliance performance?
• How would you manage a significant compliance issue?
• What metrics do you review regularly?
• How do you oversee outsourced activities?
• What role does the PSMF play in oversight?
• Describe your inspection experience.
• How do you prioritise pharmacovigilance risks?
• How do you manage senior stakeholder interactions?

Technical Topics Frequently Discussed

• Signal management
• Risk management plans
• PSMF maintenance
• Vendor oversight
• CAPA management
• Inspection readiness
• Quality systems
• Governance frameworks

Leadership Topics

Senior QPPV interviews frequently explore leadership, decision-making, risk management and communication skills in addition to technical pharmacovigilance knowledge.

Practical Perspective

The strongest candidates demonstrate both technical knowledge and the ability to exercise oversight over complex pharmacovigilance systems.

Inspection findings

Inspection findings are a critical and recurrent focus of senior pharmacovigilance interviews. A candidate's experience with inspection findings demonstrates their operational competence, regulatory understanding, governance capability and ability to drive remediation through effective CAPA and verification.

This section summarises regulatory context, typical categories and examples of findings, detailed practical implementation steps for managing findings, governance considerations, inspection relevance to PSMF and vendor oversight, evidence expectations for regulators, handling remote inspections and portals, and interview‑relevant framing for describing experience.

Regulatory context

• Regulatory authorities commonly inspecting PV systems include the European Medicines Agency (EMA), national competent authorities (e.g., MHRA), the U.S. Food and Drug Administration (FDA), Japan’s PMDA and others. Each authority has specific inspection formats and follow‑up expectations, but shared principles apply: clear identification of non‑conformities, expectation of timely and adequate company responses, and evidence that corrective and preventive actions have been implemented and verified for effectiveness.
• Authorities typically classify findings by severity (critical/major/minor or similar). The FDA issues inspectional observations (Form FDA 483) and may follow with Warning Letters; EU authorities may issue inspection reports categorising observations and request formal remediation plans.
• Regulatory guidance that frames inspection expectations includes EU GVP modules, ICH guidelines (e.g., E2A–E2E), national PV legislation and applicable GMP/GCP principles where they intersect with PV activities (e.g., clinical trial safety reporting).

Common types of PV inspection findings

Typical findings observed across regulators include, but are not limited to:

• Incomplete or missing PSMF information, outdated or inconsistent PSMF content.
• Failures in individual case safety report (ICSR) processing: missed expedited reports, delayed reporting, incomplete narratives, inconsistent causality or seriousness determination, or missing source documents.
• Safety database validation or system‑to‑system transfer issues, including lack of evidence for user acceptance testing, change control, and reconciliation processes.
• Deficient signal management: failure to document signal detection, assessment, or follow‑up; incomplete signal tracking.
• Risk minimisation and RMP deficiencies: inadequate implementation of RMMs, missing evidence of effectiveness evaluations.
• Vendor oversight gaps: missing or inadequate PV agreements, lack of documented oversight/audit of third parties (CROs, vendors), or evidence of delegated activities not executed per contract.
• Training and qualification gaps: missing training records for personnel performing regulated PV functions.
• Quality system and CAPA weaknesses: incomplete root cause analysis, ineffective CAPA design, delayed implementation, or inadequate verification of effectiveness.
• Data integrity and electronic records issues: lack of audit trails, poor access controls, or inability to produce required electronic records.
• Aggregate reporting deficiencies: delayed or missing PSURs/PBRERs, incomplete diagrams for global submission history.

Classification and prioritisation of findings

• Classify findings by severity and systemic impact (critical/major/minor) and by business impact (patient safety, regulatory compliance, commercial).
• Prioritise remediation on findings that:
• Indicate patient safety risk (high priority)
• Affect regulatory timelines (e.g., missed expedited reports)
• Represent systemic control failures (broadest scope)
• Use a formal triage approach on receipt of the inspection report:
• Immediate actions for safety signals and reporting breaches
• Contain and preserve evidence for areas under investigation
• Assign ownership and set target completion dates, with provisional milestones

Practical implementation: step‑by‑step management of inspection findings

1. Receipt and logging
2. Log the inspection report and each finding in a central findings/CAPA tracking system with unique identifiers.

3. Record key metadata: date received, inspectorate, finding severity, responsible owner, proposed due date.

4. Immediate containment (if required)

5. For findings implicating patient safety or ongoing reporting breaches, implement immediate containment (e.g., stop gap processes, manual reconciliations, temporary SOPs) and document actions.

6. Triage and assignment

7. Convene a rapid response team including QPPV, Head of PV, Quality, Legal (if needed), IT and vendor management.

8. Allocate lead and supporting owners for each finding.

9. Root cause analysis (RCA)

10. Perform structured RCA (e.g., 5 Whys, Fishbone) to identify underlying systemic causes, not just proximate failures.

11. Document evidence and link RCA conclusions to proposed CAPAs.

12. CAPA development

13. Define corrective (fix) and preventive (prevent recurrence) actions with clear deliverables, timelines, responsible persons, and acceptance criteria.

14. Ensure CAPAs are proportionate to the finding severity and address systemic issues when indicated.

15. Governance review and approval

16. Present proposed CAPA plan to the appropriate governance forum (PV Quality Board, Compliance Committee, or Executive Management) for approval and resource allocation.

17. QPPV signs off on clinical safety‑significant CAPAs and confirms acceptability of proposed patient safety mitigation.

18. Implementation and documentation

19. Execute CAPAs per plan, ensuring changes to SOPs, systems, vendor contracts, training and operational workflows are documented and version controlled.

20. Maintain a clear audit trail linking each implemented action to the original finding.

21. Verification of effectiveness

22. Design and execute verification activities (e.g., targeted audits, monitoring metrics, data reconciliations) against predefined success criteria.

23. Document results and retain evidence: audit reports, monitoring outputs, reconciliations, screenshots, system logs.

24. Closure and submission to authority

25. Prepare a formal closure package that includes RCA, CAPA evidence, verification results, and any revised SOPs or records.

26. Submit the response package to the inspectorate in the format and timeframe requested and maintain internal records.

27. Post‑closure monitoring

    • Monitor for recurrence via ongoing quality oversight, management metrics and periodic audits.

Timelines and regulator expectations

• Regulatory expectations for response timing vary:
• FDA commonly expects a written response to Form FDA 483 within 15 business days with proposed corrective actions.
• EMA/European competent authorities typically expect a timely, robust remediation plan; practice commonly employs 15–30 calendar days for initial responses but formal deadlines can vary and are sometimes set in the inspection report or subsequent correspondence.
• Always check the inspection cover letter and subsequent authority communications for explicit timelines and format expectations.
• When uncertain, acknowledge receipt immediately, provide an interim response with initial containment measures, and commit to a delivery date for the full CAPA package.

Evidence and documentation: what inspectors will expect to see

• Complete and up‑to‑date PSMF, including accurate descriptions of the PV system, single point of contact, and lists of subcontractors.
• SOPs and controlled documents relevant to the finding (with approved version history).
• ICSR listings, reconciliation logs, and evidence of timely reporting (system reports, timestamps).
• Vendor contracts, PV agreements, delegated responsibility matrices and audit summaries.
• Validation documentation for safety databases and system change control.
• RCA reports, CAPA plans (with timelines and owners), implementation records, training records.
• Verification evidence: audit reports, monitoring dashboards, reconciliation results, and meeting minutes demonstrating governance oversight.

Vendor and outsourced activity findings

• Common vendor‑related observations include inadequate PV agreements, missing evidence that delegated tasks were performed, lack of oversight/audit, and inconsistent handling between sponsor and vendor.
• Practical controls:
• Maintain up‑to‑date PV Master Services Agreements (MSAs) and Technical Annexes detailing deliverables and timelines.
• Enforce documented oversight plan: periodic vendor audits, KPIs, trending and review of performance indicators.
• Document escalation paths and interface owners; ensure vendor CAPAs are reviewed and verified.
• Include evidence of vendor training and qualifications in PSMF or as annexed records.

Governance and escalation

• Governance should ensure executive visibility for major or systemic findings:
• Escalate critical/major findings to Compliance Committee and Executive Management.
• QPPV bears responsibility for clinical safety and must be involved in decision points where patient safety is implicated.
• Establish a single point of contact for inspection correspondence and for coordinating cross‑functional inputs (Quality, Legal, Regulatory Affairs, IT, Procurement).
• Use a documented governance framework to approve CAPAs, allocate resources, and sign off verification.

Metrics and trending for inspection management

Use operational and governance metrics to monitor inspection response performance and readiness: - Number of open inspection findings by severity and by owner. - Average time from finding receipt to CAPA implementation. - Percent of CAPAs with verified effectiveness. - Repeat findings rate (same issue recurring). - Time to regulatory submission of response and time to agreement/closure. - Vendor performance metrics: SLA compliance, audit findings, overdue actions.

Remote inspections, portals and electronic evidence

• Regulators increasingly use remote inspections and secure document portals. Prepare for:
• Controlled document packages, with version control and redaction where necessary (redact personal data in line with GDPR and jurisdictional rules).
• Secure transmission of screenshots, system logs and audit trails.
• Real‑time engagement via teleconferences, with a named lead to coordinate incoming requests.
• Maintain a single evidence bank with indexed folders mapped to inspection findings to speed retrieval.

PSMF and inspection findings

• The PSMF is often inspected directly; ensure it reflects actual state of operations and contains accurate lists of QPPV, locally responsible persons, PV system description, and outsourced activities.
• When findings relate to the PSMF (e.g., inconsistencies), update the PSMF and document the change history and rationale; submit updated PSMF pages if requested by the authority.

Practical examples of findings and typical remediation elements (illustrative)

• Finding: Recurrent failure to submit serious unexpected suspected adverse reaction (SUSAR) reports within regulatory timelines.
• RCA: Automation gaps in data transfer from clinical vendor; inadequate escalation rules.
• CAPA: Implement manual interim reconciliation procedure, reconfigure system interfaces, retrain staff, revise SOPs, and audit completed reconciliations.

• Verification: Targeted audit of recent ICSRs; cross‑site reconciliation reports showing sustained compliance.

• Finding: Signal assessment documentation incomplete.

• RCA: No standardised template and unclear ownership.
• CAPA: Introduce standard signal assessment form, define timelines and ownership in SOP, train PV and medical teams.
• Verification: Review last three signal assessments for completeness and adherence.

Inspection findings in interviews: how to present your experience

When asked about inspection findings in an interview, structure responses to demonstrate technical control, leadership and governance:

• Context: Briefly describe the inspection type and authority.
• Role: Define your role (QPPV, functional lead) and responsibilities.
• Finding: Describe the finding objectively and its severity (no identifiable personal data).
• Actions: Outline immediate containment, RCA method, CAPA design and governance approvals.
• Implementation: Summarise implementation steps, resource allocation and timelines.
• Verification and outcome: Explain how effectiveness was tested and whether the authority accepted the response; highlight lessons learned and system improvements.
• Metrics and sustainability: Describe measures introduced to prevent recurrence and how ongoing oversight is provided.

Sample interview prompt and concise response structure: - Question: "Describe a significant inspection finding you managed." - Response outline: - One‑sentence context (authority and scope) - Clear statement of the finding and risk - Specific RCA and the root cause identified - Key CAPAs (3–4 actions) with timelines - Evidence of verification and outcome (inspection report closure or accepted response) - Governance oversight and lessons learned

Using inspections to drive continuous improvement

• Treat inspection findings as opportunities to strengthen the PV system.
• Feed findings into periodic PV system risk assessments, audit plans and training programs.
• Implement systemic changes (e.g., governance improvements, automated controls, harmonised SOPs) rather than cosmetic fixes to prevent recurrence.

Wrap‑up

Inspection findings test the robustness of PV systems, the clarity of governance and the QPPV’s ability to coordinate a cross‑functional response. Demonstrable experience with methodical RCA, appropriately scoped CAPAs, rigorous verification and clear governance will be a distinguishing feature in senior QPPV interviews. Provide concise, evidence‑based descriptions of inspection work, show command of regulatory expectations, and demonstrate ongoing use of findings to improve patient safety and system compliance.

Last reviewed: June 2026